Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) designed to activate GHRH receptors in the anterior pituitary. It is widely studied in endocrinology and metabolic research for its role in regulating growth hormone secretion and downstream signaling pathways involving insulin-like growth factor-1 (IGF-1).
In research and preclinical settings, tesamorelin is examined for its effects on growth hormone pulsatility, lipid metabolism, body composition signaling, and hypothalamic–pituitary axis regulation. Its structure allows researchers to explore endogenous growth hormone stimulation mechanisms rather than direct hormone replacement models.
Research involving tesamorelin focuses on hormonal signaling dynamics, metabolic regulation, and endocrine feedback mechanisms rather than therapeutic or clinical application.
